Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) (clinicaltrials.gov) - Jun 30, 2026 - P2 | N=197 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
|